TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: salivary secretor status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct performance of positive pressure ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct performance of chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of addressing FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective titres (≥ 0.5 IU/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Use of piritramid
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: maintenance of weight loss > 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in total serum cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of cultivable Streptococcus mutans and Lactobacillus sp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived likelihood of neighbors exercising
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prolonged bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary hepatic recurrence
Endpoint domain: Mortality/survival
Primary endpoint: hemorrhagic stroke risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: composite death/MI/stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of VT/VF events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fractional Area Change (FAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease of VAS (Visual Analog Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of Lequesne's index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pNN50 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cognitive function preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatization scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cranial extension of sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total number of segments blocked
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with maximal cranial block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Markers of bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of mycophenolic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of mycophenolic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total no-flow time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median cumulative interruption time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median number of interruption events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of moderate to severe depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to allogeneic blood
Endpoint domain: Adverse events/effects
Primary endpoint: high end-state function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rates of continued breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for pharmacotherapy for neonatal withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Functioning improvements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum under‐O‐glycosylated IgA1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of advanced PCa
Endpoint domain: Mortality/survival
Primary endpoint: risk of being diagnosed with low-risk PCa
Endpoint domain: Mortality/survival
Primary endpoint: Mean logarithm of the minimal angle of resolution best‐corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete subretinal fluid reabsorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoglycemia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Integrated incremental responses of total GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Integrated incremental responses of total GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lung WR of 123I-MIBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: L/M ratio in early images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FRAIL score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal from prefrailty to robust phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight z-score at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height z-score at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance of Th1/Th2 cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: abdominal visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intrahepatic fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prognostic role of serum free mGSTP1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity for detection of Hodgkin lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of US/chest radiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karlsson scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sefton grading system satisfactory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Talar tilt angle improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement rate for combined symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total daily insulin dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postexercise energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of treatment aim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of infections
Endpoint domain: Adverse events/effects
Primary endpoint: Obstructive problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprotected receptive anal intercourse with a negative or unknown-serostatus partner
Endpoint domain: Adverse events/effects
Primary endpoint: save millions of lives
Endpoint domain: Mortality/survival
Primary endpoint: Severity of hay fever symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student performances at collecting clinical history
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication skills subscales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student perceptions about the realism of the case
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: plasma HIV‐1 RNA levels <400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to event (permanent discontinuation of randomized therapy or viral rebound)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of drug‐related nausea, vomiting, rash and oral/perioral paresthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adolescent smokers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cost per student not smoking at 2 years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Belief of being a smoker at age 16
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of BoNTA monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of BoNTA monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: complete response after treatment
Endpoint domain: Mortality/survival
Primary endpoint: Delay in DTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cocaine urine toxicology outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to alleviate fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of bronchoconstriction induced by HS inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resolution of bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bladder neck contracture (BNC) rate
Endpoint domain: Adverse events/effects
Primary endpoint: BMI z-score reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost-effectiveness ratio per unit BMI avoided
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total postprandial TG response (incremental AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chylomicron TG iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VLDL1 TG iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy absolute risk difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional wall motion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular end‐diastolic areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intrapulmonary shunt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in colony-forming units (CFUs) of Candida spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: length and diameter of the nipple
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Postoperative day 1 aqueous flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PGE2 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of TBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma 5-HIAA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum lifting load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isokinetic peak torque of the back extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Action Research Arm Test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed Manual Muscle Test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in local anesthetic/opioid requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with wear-time criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success at EOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause 60-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: RQLQ measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: albumin-to-creatinine ratio levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: plasma monocyte chemoattractant protein-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: daytime MSNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depressiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes to home medication list
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potential severity of medication discrepancies
Endpoint domain: Adverse events/effects
Primary endpoint: Chance of harm from medication discrepancies
Endpoint domain: Adverse events/effects
Primary endpoint: hSBA titres ≥ 4 against fHbp, NadA and PorA test strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean ELISA concentrations (GMCs) against NHBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequencies of solicited reactions after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Attentional bias to disgust stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vigilance to angry faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average of ARTSS and ARMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity in identifying fallers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of 4RMP compared to 9INH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of source memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: prevalence of bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detectable anti-D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the frequency of all seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Menstrual pain score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BRS-6 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of PRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of accessing the World Wide Web to address patient-related questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Comfort level in using on-line databases
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of accessing on-line databases
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: minimum in stent area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Cholesterol (TC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative wound drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viscoelastic properties of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of hypotension during dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disability improvement at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in lipid profile (LDLc reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in leukocyte/endothelium interactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients gaining ≥15 letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline central retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: edema resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant change on the Panic Disorder Severity Scale‐Self Report (PDSS‐SR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive effect on DSM‐IV panic disorder status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year mortality after STEMI
Endpoint domain: Mortality/survival
Primary endpoint: Pain score during wound care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain score after wound care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum levels of MMP-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue concentration of MMP-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF-free status at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ITA free flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects with at least 1 ACF reidentified after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of subjects with new ACF identified after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean percent SMH recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent net erosion resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: X-ray resolution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cavity reducing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-FXa activity A(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t½ (elimination half-life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time to perturbation during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHEOPS pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of change of CIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Range of motion (RANG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RVR (Renal Vascular Resistance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement of physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rates (≥0.15 µg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean time to 75% event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: average change in mean 2-hour blood glucose level after meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average change in hemoglobin A1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: all-cause death at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: ChB(Vol) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ChB(Vel) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28-CRP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes